首页|Ethanolamine as a biomarker and biomarker-based therapy for diabetic retinopathy in glucose-well-controlled diabetic patients

Ethanolamine as a biomarker and biomarker-based therapy for diabetic retinopathy in glucose-well-controlled diabetic patients

扫码查看
Diabetic retinopathy(DR)is the leading cause of blindness among the working-age population.Although controlling blood glucose levels effectively reduces the incidence and development of DR to less than 50%,there are currently no diagnostic biomarkers or effective treatments for DR development in glucose-well-controlled diabetic patients(GW-DR).In this study,we established a prospective GW-DR cohort by strictly adhering to glycemic control guidelines and maintaining regular retinal examinations over a median 2-year follow-up period.The discovery cohort encompassed 71 individuals selected from a pool of 292 recruited diabetic patients at baseline,all of whom consistently maintained hemoglobin A1c(HbA1c)levels below 7%without experiencing hypoglycemia.Within this cohort of 71 individuals,21 subsequently experienced new-onset GW-DR,resulting in an incidence rate of 29.6%.In the validation cohort,we also observed a significant GW-DR incidence rate of 17.9%.Employing targeted metabolomics,we investigated the metabolic characteristics of serum in GW-DR,revealing a significant association between lower levels of ethanolamine and GW-DR risk.This association was corroborated in the validation cohort,exhibiting superior diagnostic performance in distinguishing GW-DR from diabetes compared to the conventional risk factor HbA1c,with AUCs of 0.954 versus 0.506 and 0.906 versus 0.521 in the discovery and validation cohorts,respectively.Furthermore,in a streptozotocin(STZ)-induced diabetic rat model,ethanolamine attenuated diabetic retinal inflammation,accompanied by suppression of microglial diacylglycerol(DAG)-dependent protein kinase C(PKC)pathway activation.In conclusion,we propose that ethanolamine is a potential biomarker and represents a viable biomarker-based therapeutic option for GW-DR.

Glucose-well-controlled diabetic patientsDiabetic retinopathyBiomarkerHbA1cEthanolamineBiomarker-based treatment

Guangyi Hu、Liping Gu、Ruonan Wang、Qizhi Jian、Kangjia Lv、Mengxue Xia、Mengyu Lai、Tingting Shen、Jing Hu、Sen Yang、Cunqi Ye、Xiaonan Zhang、Yufan Wang、Xun Xu、Fang Zhang

展开 >

National Clinical Research Center for Eye Diseases,Department of Ophthalmology,Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200080,China

Eye Institute of Shanghai Jiao Tong University School,Shanghai 200080,China

Shanghai Key Laboratory of Fundus Diseases,Shanghai 200080,China

Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Diseases,Shanghai 200080,China

Department of Endocrinology and Metabolism,Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200080,China

Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology,Life Sciences Institute,Zhejiang University,Hangzhou 310058,China

Kidney Disease Center,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China

Shanghai Engineering Center for Precise Diagnosis and T

展开 >

Key R&D project of the National Ministry of Science and TechnologyMajor Research Plan of the National Natural Science Foundation of ChinaMajor Research Plan of the National Natural Science Foundation of ChinaNational Natural Science Foundation of ChinaNational Natural Science Foundation of ChinaShanghai Jiaotong University-Gaofeng Clinical Medicine Grant

2023YFA180110092357307920571063217117781870610

2024

科学通报(英文版)
中国科学院

科学通报(英文版)

CSTPCD
ISSN:1001-6538
年,卷(期):2024.69(12)